IL269743B - Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions - Google Patents

Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions

Info

Publication number
IL269743B
IL269743B IL269743A IL26974319A IL269743B IL 269743 B IL269743 B IL 269743B IL 269743 A IL269743 A IL 269743A IL 26974319 A IL26974319 A IL 26974319A IL 269743 B IL269743 B IL 269743B
Authority
IL
Israel
Prior art keywords
alkyl
compound
group
optionally substituted
formula
Prior art date
Application number
IL269743A
Other languages
English (en)
Hebrew (he)
Other versions
IL269743A (en
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of IL269743A publication Critical patent/IL269743A/en
Publication of IL269743B publication Critical patent/IL269743B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
IL269743A 2017-04-05 2018-04-04 Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions IL269743B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762482134P 2017-04-05 2017-04-05
PCT/US2018/026091 WO2018187473A1 (en) 2017-04-05 2018-04-04 Methods and compositions for treating retina-associated disease using ccr3-inhibitors

Publications (2)

Publication Number Publication Date
IL269743A IL269743A (en) 2019-11-28
IL269743B true IL269743B (en) 2022-09-01

Family

ID=62067800

Family Applications (1)

Application Number Title Priority Date Filing Date
IL269743A IL269743B (en) 2017-04-05 2018-04-04 Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions

Country Status (20)

Country Link
US (2) US11590118B2 (https=)
EP (2) EP3606521B1 (https=)
JP (1) JP7179755B2 (https=)
KR (1) KR102658724B1 (https=)
CN (1) CN110650740A (https=)
AU (2) AU2018248425B2 (https=)
BR (1) BR112019020430A2 (https=)
CA (1) CA3058654A1 (https=)
CL (1) CL2019002839A1 (https=)
CO (1) CO2019012336A2 (https=)
EA (1) EA201992356A1 (https=)
ES (2) ES2950453T3 (https=)
IL (1) IL269743B (https=)
MX (1) MX394915B (https=)
MY (1) MY199462A (https=)
NZ (1) NZ757769A (https=)
SG (1) SG11201909207VA (https=)
TW (1) TW201841636A (https=)
UA (1) UA125658C2 (https=)
WO (1) WO2018187473A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909245PA (en) * 2017-04-05 2019-11-28 Alkahest Inc Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
CN112789044A (zh) * 2018-09-26 2021-05-11 万能溶剂有限公司 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
AU2021287906B2 (en) * 2020-06-11 2025-09-11 Alkahest Inc. Methods of improving retina-associated disease outcome using CCR3-inhibitors
CN112322719A (zh) * 2020-11-06 2021-02-05 温州医科大学 循环血外泌体miRNA作为视网膜静脉阻塞疾病诊断标志物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2002112800A (ru) 2002-05-16 2004-03-10 Евгений Ильич Зарайский (RU) Способ лечения диабетической ретинопатии
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
RU2014126070A (ru) 2011-12-01 2016-01-27 Глэксо Груп Лимитед Способы лечения и предотвращения глазных заболеваний
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
SG11201909245PA (en) 2017-04-05 2019-11-28 Alkahest Inc Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Also Published As

Publication number Publication date
US11951102B2 (en) 2024-04-09
EP4245295A3 (en) 2023-11-01
MY199462A (en) 2023-10-30
ES3046717T3 (en) 2025-12-02
IL269743A (en) 2019-11-28
TW201841636A (zh) 2018-12-01
JP2020513004A (ja) 2020-04-30
US20240024305A1 (en) 2024-01-25
EP3606521B1 (en) 2023-04-19
EP4245295A2 (en) 2023-09-20
NZ757769A (en) 2025-10-31
JP7179755B2 (ja) 2022-11-29
KR20190131121A (ko) 2019-11-25
KR102658724B1 (ko) 2024-04-18
MX394915B (es) 2025-03-24
BR112019020430A2 (pt) 2021-03-30
EA201992356A1 (ru) 2020-03-23
CO2019012336A2 (es) 2020-04-01
US20210106577A1 (en) 2021-04-15
CN110650740A (zh) 2020-01-03
MX2019012012A (es) 2019-12-11
UA125658C2 (uk) 2022-05-11
US11590118B2 (en) 2023-02-28
AU2024204133B2 (en) 2026-03-26
ES2950453T3 (es) 2023-10-10
EP3606521A1 (en) 2020-02-12
AU2024204133A1 (en) 2024-07-04
CL2019002839A1 (es) 2020-06-05
WO2018187473A1 (en) 2018-10-11
SG11201909207VA (en) 2019-11-28
CA3058654A1 (en) 2018-10-11
AU2018248425A1 (en) 2019-10-31
EP4245295B1 (en) 2025-08-06
AU2018248425B2 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
US11951102B2 (en) Methods and compositions for treating retina-associated disease using CCR3-inhibitors
TWI833535B (zh) 賽佩普斯特(Sepetaprost)及Rho激酶抑制劑之組合醫藥
WO2019124489A1 (ja) セペタプロストとep2アゴニストとの組み合わせ医薬
TWI803488B (zh) Nk-1拮抗劑組合及治療突觸核蛋白病症之方法
TW201929854A (zh) 含有吡啶基胺乙酸化合物之醫藥製劑
HK40012545A (en) Methods and compositions for treating retina-associated disease using ccr3-inhibitors
TW201442706A (zh) 含有四氫吡喃基胺基環戊基羰基四氫吡啶并吡啶衍生物作爲有效成分之後眼部疾病之預防或治療劑
CN111491636A (zh) 奥米帕格的组合
HK40102807B (en) Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
HK40102807A (en) Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
HK40029828A (en) Omidenepag combination
TW201919597A (zh) 利用新斯的明(neostigmine)及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法